Advertisement

Topics

EC approval for adalimumab biosimilar Imraldi

05:11 EDT 1 Sep 2017 | Generics and Biosimilars Initiative

Samsung Bioepis announced on 25 August 2017 that it had received European Commission (EC) approval for its biosimilar adalimumab product Imraldi.

Original Article: EC approval for adalimumab biosimilar Imraldi

NEXT ARTICLE

More From BioPortfolio on "EC approval for adalimumab biosimilar Imraldi"

Quick Search
Advertisement
 

Relevant Topic

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...